Jian Xin Chen
Directeur Technique/Scientifique/R&D chez BIOMICS BIOPHARMA LTD
Profil
Jian Xin Chen is currently the Chief Technology Officer & Vice President at Biomics Biotechnologies Co., Ltd.
and the Chief Technology Officer at Biomics Biopharma Ltd.
Prior to his current positions, he worked as a Principal at Arbutus Biopharma Corp.
and Alnylam Pharmaceuticals, Inc. Chen received his undergraduate degree from Wuhan University, his doctorate from the University of British Columbia in 1991, and his graduate degree from the Chinese Academy of Sciences in 1984.
Postes actifs de Jian Xin Chen
Sociétés | Poste | Début |
---|---|---|
BIOMICS BIOPHARMA LTD | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Biomics Biotechnologies Co., Ltd.
Biomics Biotechnologies Co., Ltd. BiotechnologyHealth Technology Biomics Biotechnologies Co., Ltd. develops ribonucleic acid interference based treatment products. Its products offer treatments for Age-related Macular Degeneration (AMD), Hepatitis B, bladder cancer, and other diseases. The company was founded by York Yuan Zhu on February 17, 2006 and is headquartered in Nantong, China. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
Anciens postes connus de Jian Xin Chen
Sociétés | Poste | Fin |
---|---|---|
ARBUTUS BIOPHARMA CORPORATION | Corporate Officer/Principal | - |
ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Jian Xin Chen
University of British Columbia | Doctorate Degree |
Chinese Academy of Sciences | Graduate Degree |
Wuhan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
BIOMICS BIOPHARMA LTD | Process Industries |
Entreprise privées | 1 |
---|---|
Biomics Biotechnologies Co., Ltd.
Biomics Biotechnologies Co., Ltd. BiotechnologyHealth Technology Biomics Biotechnologies Co., Ltd. develops ribonucleic acid interference based treatment products. Its products offer treatments for Age-related Macular Degeneration (AMD), Hepatitis B, bladder cancer, and other diseases. The company was founded by York Yuan Zhu on February 17, 2006 and is headquartered in Nantong, China. | Health Technology |